Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT06693362RecruitingPhase 1
Stem cell therapy for severe viral pneumonia
This trial tests whether injecting stem cells from the womb's blood supply can help treat severe viral pneumonia. It aims to improve recovery for people who are very sick and need hospital care.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07535645RecruitingPhase 1/Phase 2
Baricitinib for Low Platelet Counts After Bone Marrow Transplant
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Beijing, Beijing MunicipalityAges 18–70 - NCT07534033RecruitingPhase 2
Probiotic LR607 for newly diagnosed lung cancer
This study tests whether a probiotic supplement (LR607) can help patients with newly diagnosed non-small cell lung cancer—a common type of lung cancer. Probiotics are beneficial bacteria that may help your immune system fight cancer alongside standard treatments.
GuangzhouAges 18–80 - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT07540260Recruiting
Imaging-Guided Radiation Therapy for Advanced Kidney Cancer
This trial uses two types of PET scans to better target radiation therapy in patients with advanced clear cell kidney cancer that has spread or returned. The goal is to combine radiation with standard drug treatments to improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07541391RecruitingPhase 1
CAR T-cell therapy for relapsed kappa myeloma
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Melbourne, VictoriaAges 18 years+ - NCT06750133RecruitingPhase 1
CNK-UT cell therapy for steroid-resistant graft-versus-host disease
This trial tests a new cell therapy called CNK-UT for people with severe graft-versus-host disease (aGVHD) that hasn't improved with steroid treatment after a stem cell transplant. The goal is to see if it can help control the immune reaction.
Fuzhou, FujianAges 14–70 - NCT06751199Recruiting
Stem cells combined with islet transplant for diabetes
This trial tests if umbilical cord stem cells can improve the success of islet cell transplants for people with diabetes whose own pancreas no longer makes enough insulin. It aims to help patients achieve better blood sugar control and reduce dangerous low blood sugar episodes.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06749691RecruitingPhase 2
Liposomal irinotecan and apatinib for extensive-stage small cell lung cancer
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT05610865RecruitingPhase 1
Stem cell treatment for chronic diabetic foot ulcers
This Phase 1 study tests whether stem cells taken from fat tissue (after a small procedure) can help heal a long-lasting diabetic foot ulcer. It mainly aims to help ulcers that are limited to soft tissue and have good blood flow to the foot.
Lahore, Punjab ProvinceAges 20–60 - NCT07525466RecruitingPhase 1/Phase 2
New drug combination for NK/T-cell lymphoma with immune complications
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
BeijingAges 18 years+ - NCT07528352RecruitingPhase 1
Radiation Plus Antibody Therapy for Difficult-to-Treat Lymphoma
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT07528105RecruitingEarly Phase 1
CAR-T Cell Therapy for Early-Stage Type 1 Diabetes
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
ShanghaiAges 18–40 - NCT06642324Recruiting
HPV and genetics in head and neck cancer study
This study looks at how HPV infection and genetic changes relate to head and neck squamous cell carcinoma. If you have this type of cancer, joining could help doctors learn more about the disease and improve future treatments.
Dhaka, Dhaka DivisionAges 18 years+ - NCT05610878RecruitingPhase 1
Stem cell help to improve fat grafting results
This early-phase study tests whether “preconditioned” stem cells from fat tissue can improve the look of fat transferred during liposuction and grafting. If you qualify, you may receive stem cells along with fat grafting to see how well it works and how safe it is.
Lahore, Punjab ProvinceAges 18–50 - NCT06752785RecruitingPhase 1
CAR-T cell therapy for children with ALL and minimal residual disease
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
Guangzhou, GuangdongAges 1–18 - NCT06754267RecruitingPhase 2
Studying a new drug combo for Ph+ B-ALL
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06752798RecruitingPhase 2
Trilaciclib to protect bone marrow after head and neck cancer surgery and chemoradiation
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Changsha, HunanAges 18–70 - NCT05671614Recruiting
Prevent muscle stem cell failure after critical illness
This trial studies ways to improve recovery of skeletal muscle in people who have been very sick in the ICU. It focuses on preventing problems with the body’s muscle “repair cells” after critical illness.
Prague, Czech RepublicAges 18 years+ - NCT06756217Recruiting
PET scan to check early response to immunotherapy before lung cancer surgery
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.